Adjuvant Therapy for Melanoma: Past, Current, and Future Developments

Area of Science:

• Oncology
• Dermatology
• Clinical Trials

Background:

• Adjuvant therapies aim to eliminate residual cancer cells post-surgery.
• Recent decades saw advancements in immunotherapy and targeted therapy for advanced melanoma.

Purpose of the Study:

• To review the evolution of adjuvant therapies in melanoma over 50 years.
• To focus on recent clinical trial developments in adjuvant melanoma treatment.

Main Methods:

• Review of clinical trials and scientific literature on adjuvant melanoma therapies.
• Analysis of treatment outcomes, including recurrence-free and overall survival, and toxicity profiles.

Main Results:

• Anti-CTLA-4 antibody ipilimumab was the first adjuvant therapy to improve survival but had high toxicity.
• Adjuvant anti-PD-1 agents (nivolumab, pembrolizumab) and BRAF-directed therapy demonstrated superior recurrence-free survival with better tolerability.
• Anti-PD-1 or BRAF-directed therapy is now the standard of care for adjuvant melanoma treatment.

Conclusions:

• Adjuvant therapy for melanoma has been revolutionized by anti-PD-1 and BRAF-directed treatments.
• Further research is needed to optimize adjuvant therapy timing and minimize long-term toxicity.
• Neoadjuvant approaches are under investigation and may complement adjuvant strategies.